A meta-analysis comparing the efficacy of four 5-HT3-receptor antagonists for acute chemotherapy-induced emesis
The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index.
Abstract
Goals of work Comparing antiemetic efficacy of different 5-HT(3)-receptor antagonists (5-HT(3)RAs) is difficult due to inter-study variability. Therefore, a meta-analysis was performed to comparatively evaluate dolasetron, granisetron, ondansetron and tropisetron for acute chemotherapy-induced nausea and vomiting (CINV).Patients and methods Comparisons between 5-HT(3)RAs were based on 44 randomized studies (including 12,343 patients) identified by MEDLINE, CANCERLIT or EMBASE searches and subcategorized by chemotherapy type (cisplatin- or non-cisplatin-based).Main results When all studies were combined, granisetron was equivalent to ondansetron (n = 27), and showed an advantage vs tropisetron (p = 0.018; n = 12). Ondansetron vs tropisetron (n = 11) and ondansetron vs dolasetron (n = 3) revealed equivalence in each comparison. An advantage for 3 mg granisetron vs 8 mg ondansetron was found in non-cisplatin-based studies (p = 0.015; n = 6). Overall equivalence was seen between ondansetron, 24 or 32 mg, and granisetron, 2 or 3 mg, for all studies (n = 13). There was a possible advantage for higher (24 or 32 mg) vs lower (8 mg) ondansetron dose regimens with cisplatin-based trials (n = 6). No differences were seen between 3 and 1 mg granisetron doses (n = 6).Conclusions Efficacy of 5-HT(3)RAs for preventing CINV following cisplatin- and non-cisplatin-based chemotherapy is comparable, with the exception of granisetron vs tropisetron. Some differences were noted in dosing subanalyses.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, there are ample data demonstrating the efficacy of these agents in CINV and postoperative nausea and vomiting (PONV) in treating acute, delayed, and anticipatory nausea and vomiting.70, 71”
Citations
Cites
Beta blockade during and after myocardial infarction: An overview of the randomized trials
Yusuf, S., Peto, R., Lewis, J., Collins, R., & Sleight, P. (1985) · Progress in Cardiovascular Diseases · doi:10.1016/s0033-0620(85)80003-7 · Cited by 3,205 · cited 1×
“Combined odds ratios were generated using Mantel-Haenszel pooling of contingency tables (fixed effect model as the standard approach) [68, 70].”
MethodMeta‐Analysis Of Controlled Clinical Trials
Whitehead, A. (2002) · doi:10.1002/0470854200 · Cited by 827
Prognostic value of vascular endothelial growth factor expression in gastric carcinoma
Maeda, K., Chung, Y. S., Ogawa, Y., Kang, S., Ogawa, M., Sawada, T., & Sowa, M. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960301)77:5<934::aid-cncr20>3.0.co;2-3 · Cited by 639
Gralla, R., Lichinitser, M., Van der Vegt, S., Sleeboom, H., Mezger, J., Peschel, C., Tonini, G., Labianca, R., Macciocchi, A., & Aapro, M. (2003) · Annals of Oncology · doi:10.1093/annonc/mdg417 · Cited by 467
Eisenberg, P., Figueroa‐Vadillo, J., Zamora, R., Charu, V., Hajdenberg, J., Cartmell, A., Macciocchi, A., & Grunberg, S. (2003) · Cancer · doi:10.1002/cncr.11817 · Cited by 400
Aapro, M. S., Grunberg, S. M., Manikhas, G. M., Olivares, G., Suarez, T., Tjulandin, S. A., Bertoli, L. F., Yunus, F., Morrica, B., Lordick, F., et al. (2006) · Annals of Oncology · doi:10.1093/annonc/mdl137 · Cited by 338
Kaiser, R., Sezer, O., Papies, A., Bauer, S., Schelenz, C., Tremblay, P.-B., Possinger, K., Roots, I., & Brockmöller, J. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.09.064 · Cited by 251
Nonsteroidal antiinflammatory drugs and colorectal cancer
Muscat, J. E., Stellman, S. D., & Wynder, E. L. (1994) · Cancer · doi:10.1002/1097-0142(19941001)74:7<1945::aid-cncr2820740720>3.0.co;2-c · Cited by 198
Hesketh, P. J., Navari, R. M., Grote, T., Gralla, R. J., Hainsworth, J. D., Kris, M. G., Anthony, L. B., Khojasteh, A., Tapazoglou, E., Benedict, C. R., et al. (1996) · Journal of Clinical Oncology · doi:10.1200/jco.1996.14.8.2242 · Cited by 145
Perez, E. A., Hesketh, P. J., Sandbach, J. F., Reeves, J., Chawla, S., Markman, M. M., Hainsworth, J. D., Bushnell, W., & Friedman, C. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.754 · Cited by 136
Navari, R. M., Gandara, D. R., Hesketh, P. J., Hall, S., Mailliard, J. A., Ritter, H., Friedman, C., & Fitts, D. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.5.1242 · Cited by 128
Ruff, P., Paska, W., Goedhals, L., Pouillart, R., Rivière, A., Vorobiof, D., Bloch, B., Jones, A. L., Martin, C., Brunet, R., et al. (2009) · Oncology · doi:10.1159/000227321 · Cited by 124
de Wit, R., de Boer, A. C., Linden, G., Stoter, G., Sparreboom, A., & Verweij, J. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.2045 · Cited by 123
A cost/benefit analysis: About the Precautionary Principle
Iaccarino, M. (2000) · EMBO Reports · doi:10.1093/embo-reports/kvd121 · Cited by 120
Lofters, W., Pater, J. L., Zee, B. C.-Y., Dempsey, E., Walde, D., Moquin, J.-P., Wilson, K. S., Hoskins, P. J., Guevin, R., Verma, S., et al. (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.8.2966 · Cited by 103
Ondansetron Study Group, Seynaeve, C., Schuller, J., Buser, K., Porteder, H., Belle, S. V., Sevelda, P., Christmann, D., Schmidt, M., Kitchener, H. C., et al. (1992) · British Journal of Cancer · doi:10.1038/bjc.1992.241 · Cited by 102
Jantunen, I. T., Muhonen, T. T., Kataja, V. V., Flander, M. K., & Teerenhovi, L. M. (1993) · European Journal of Cancer · doi:10.1016/0959-8049(93)90101-k · Cited by 101
Granisetron is equivalent to ondansetron for prophylaxis of chemotherapy-induced nausea and vomiting
del Giglio, A., Soares, H. P., Caparroz, C., & Castro, P. C. (2000) · Cancer · doi:10.1002/1097-0142(20001201)89:11<2301::aid-cncr19>3.0.co;2-6 · Cited by 101
BECK, T. M., Hesketh, P. J., Madajewicz, S., Navari, R. M., Pendergrass, K. B., Lester, E. P., Kish, J. A., Murphy, W. K., Hainsworth, J. D., & Gandara, D. R. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.12.1969 · Cited by 100
Gralla, R. J., Navari, R. M., Hesketh, P. J., Popovic, W., Strupp, J., Noy, J., Einhorn, L. H., Ettinger, D. S., Bushnell, W., & Friedman, C. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.4.1568 · Cited by 98
Navari, R. M., Kaplan, H. G., Gralla, R. J., Grunberg, S. M., Palmer, R. H., & Fitts, D. (1994) · Journal of Clinical Oncology · doi:10.1200/jco.1994.12.10.2204 · Cited by 85
Roila, F. (1995) · Annals of Oncology · doi:10.1093/oxfordjournals.annonc.a059320 · Cited by 85
Audhuy, B., Cappelaere, P., Martín, M., Cervantes, A. M. R., Fabbro, M., Rivière, A., Khayat, D., Bleiberg, H., Faraldi, M., Claverie, N., et al. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(96)00025-1 · Cited by 84
Antiemetics and Cancer Chemotherapy.
(1983) · Annals of Internal Medicine · doi:10.7326/0003-4819-98-4-576_6 · Cited by 82
Nitrite/ nitrate and cytokine levels in bronchoalvelar lavage fluid of lung cancer patients
Arias‐Díaz, J., Vara, E., Torres-Melero, J., García, C., Baki, W., Ramσrez-Armengol, J. A., & Balibrea, J. L. (1994) · Cancer · doi:10.1002/1097-0142(19940901)74:5<1552::aid-cncr2820740510>3.0.co;2-f · Cited by 73
Radiation-induced emesis: a prospective observational multicenter Italian trial
Maranzano, E., Latini, P., Roila, F., Angelis, V. D., Tonato, M., Ballatori, E., Favero, A. D., Ciccarese, G., Palladino, M., Galardi, A., et al. (1999) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(99)00055-3 · Cited by 72
Quality of Life Studies in Chemotherapy-Induced Emesis
Osoba, D., Zee, B. C.-Y., Warr, D. G., Kaizer, L., Latreille, J., & Pater, J. L. (2009) · Oncology · doi:10.1159/000227647 · Cited by 71
Significance and detection of dysplasia in chronic colitis
Goldman, H. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19961201)78:11<2450::aid-cncr29>3.0.co;2-z · Cited by 67
Doherty, K. M. (1999) · PubMed · Cited by 66
Noble, A., Bremer, K., Goedhals, L., Cupissol, D., & Dilly, S. (1994) · European Journal of Cancer · doi:10.1016/0959-8049(94)90461-8 · Cited by 62
Stewart, A., McQuade, B., Cronje, J. D. E., Goedhals, L., Gudgeon, A., Corette, L., Froger, X., Tubiana-Hulin, M., Laplaige, P., Roberts, J. T., et al. (2009) · Oncology · doi:10.1159/000227458 · Cited by 56
Mantovani, G., Macciò, A., Bianchi, A. C., Curreli, L., Ghiani, M., Proto, E. B., & Santona, M. C. (1996) · Cancer · Cited by 55
BRL 46470 potently antagonizes neural responses activated by 5-HT3 receptors
Newberry, N. R., Watkins, C. S., Sprosen, T. S., Blackburn, T. P., GRAHAMESMITH, D., & Leslie, R. A. (1993) · Neuropharmacology · doi:10.1016/0028-3908(93)90180-b · Cited by 50
Intravenous granisetron — establishing the optimal dose
Kamanabrou, D. (1992) · European Journal of Cancer · doi:10.1016/0959-8049(92)90629-g · Cited by 45
Is Navoban® (tropisetron) as effective as Zofran® (ondansetron) in cisplatin-induced emesis?
Marty, M. E., Kleisbauer, J. P., Fournel, P., Vergnenégre, A., Carlès, P., Loria-Kanza, Y., Simonetta, C., & de Bruijn, K. M. (1995) · Anti-Cancer Drugs · doi:10.1097/00001813-199502001-00004 · Cited by 40
Fauser, A. A., Duclos, B., Chemaissani, A., Favero, A. D., Cognetti, F., Díaz‐Rubio, E., Cortés-Funes, H., Conte, P., & Dressler, H. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(96)00132-3 · Cited by 40
Soukop, M. (1990) · PubMed · Cited by 36
Martoni, A. A., Angelelli, B., Guaraldi, M., Strocchi, E., & Pannuti, F. (1996) · European Journal of Cancer · doi:10.1016/0959-8049(95)00519-6 · Cited by 34
Bonneterre, J., & Hecquet, B. (1995) · PubMed · Cited by 32
Forni, C., Ferrari, S., Loro, L., Mazzei, T., Beghelli, C., Biolchini, A., Simoni, P., Tremosini, M., Strazzari, S., Puggioli, C., et al. (2000) · Supportive Care in Cancer · doi:10.1007/s005200050027 · Cited by 31
Aksoylar, S., Akman, S. A., Özgenç, F., & Kansoy, S. (2001) · Pediatric Hematology and Oncology · doi:10.1080/088800101316922029 · Cited by 31
Smith, I. E. (1990) · PubMed · Cited by 28
Diamond-blackfan anemia and malignancy. A case report and a review of the literature
van Dijken, P. J., & Verwijs, W. (1995) · Cancer · doi:10.1002/1097-0142(19950801)76:3<535::aid-cncr2820760331>3.0.co;2-k · Cited by 28
Perez, E. A., Navari, R. M., Kaplan, H. G., Gralla, R. J., Grunberg, S. M., Palmer, R. H., & Fitts, D. (1997) · Supportive Care in Cancer · doi:10.1007/bf01681959 · Cited by 27
Yalçn, Ş., Tekuzman, G., Baltal, E., Özşk, Y., & Barşta, İ. (1999) · American Journal of Clinical Oncology · doi:10.1097/00000421-199902000-00023 · Cited by 27
Oge, A., Alkış, N., Oge, O., & Kartum, A. (2000) · PubMed · doi:10.1179/joc.2000.12.1.105 · Cited by 25
Chua, D. T. T., Sham, J. S. T., Kwong, D. L. �., Kwok, C. C. H., YUE, A. M., Foo, Y. C., & Chan, R. (2000) · American Journal of Clinical Oncology · doi:10.1097/00000421-200004000-00016 · Cited by 24
Jantunen, I. T., Kataja, V. V., & Johansson, R. T. (1992) · Acta Oncologica · doi:10.3109/02841869209088309 · Cited by 23
Spector, J. I., Lester, E. P., Chevlen, E. M., Sciortino, D. F., Harvey, J. H., Whaley, W., Madajewicz, S., ISAACS, R. E., Homesley, H. D., Yee, S. F., et al. (1998) · The Oncologist · doi:10.1634/theoncologist.3-6-432 · Cited by 23
Krzakowski, M. J., Graham, E., Goedhals, L., Joly, F., Pawlick, M., Rapoport, B. L., Yelle, L., Lees, J. P., & McQuade, B. (1998) · Anti-Cancer Drugs · doi:10.1097/00001813-199808000-00003 · Cited by 22
Marty, M. E., Jp, K., Fournel, P., Vergnenégre, A., Carlès, P., Loria-Kanza, Y., Simonetta, C., & de Bruijn, K. M. (1995) · PubMed · Cited by 21
Barrajón, E., & Peñas, R. D. L. (2000) · Supportive Care in Cancer · doi:10.1007/s005209900120 · Cited by 20
Bubalo, J. S., Seelig, F., Karbowicz, S. H., & Maziarz, R. T. (2001) · Transplantation and Cellular Therapy · doi:10.1016/s1083-8791(01)80011-2 · Cited by 20
Herrington, J. D., Kwan, P., Young, R. R., Lagow, E., Lagrone, L. W., & Riggs, M. W. (2000) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.20.17.1318.34894 · Cited by 18
Kagoshima, M., Tomomatsu, N., Iwahisa, Y., Yamaguchi, S., Kawakami, Y., & Terasawa, M. (2008) · Pharmacology · doi:10.1159/000139463 · Cited by 16
Park, J. O., Rha, S. Y., Yoo, N. C., Kim, J. H., Roh, J. K., Min, J. S., Kim, B., & Chung, H. C. (1997) · American Journal of Clinical Oncology · doi:10.1097/00000421-199712000-00007 · Cited by 13
Dempsey, C. L., Coop, A. J., Shillington, A. C., Farley, P. A., Eberhardt, D. R., & O’Briant, S. (2004) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/61.8.781 · Cited by 13
Massidda, B., & Ionta, M. T. (1996) · Journal of Chemotherapy · doi:10.1179/joc.1996.8.3.237 · Cited by 12
Tan, M., Xu, R., & Seth, R. (2004) · Current Medical Research and Opinion · doi:10.1185/030079904125003728 · Cited by 12
Pectasides, D., Mylonakis, A., Varthalitis, J., Kostopoulou, M., Constantinou, A. I., Papazachariou, K., Antoniou, F., Dimitriadis, M., & Athanassiou, A. (2009) · Oncology · doi:10.1159/000227651 · Cited by 10
Jordan, K., Grothey, A., Kegel, T., Fibich, C., & Schöbert, C. (2005) · Oncology Research and Treatment · doi:10.1159/000082523 · Cited by 9
Self-citationBosnjak, S. M., Nešković‐Konstantinović, Z., Jovanović-Micić, D., Mitrović, L., & Radulovic, S. S. (1996) · Journal of Chemotherapy · doi:10.1179/joc.1996.8.4.315 · Cited by 9
Martoni, A. A., Piana, E., Strocchi, E., Angelelli, B., Guaraldi, M., Zamagni, C., Camaggi, C. M., & Pannuti, F. (1998) · PubMed · Cited by 9
Pinkerton, R., Jacobson, S., Leclerc, J., Cohn, R., & Cedar, E. (1993) · European Journal of Cancer · doi:10.1016/0959-8049(93)91742-4 · Cited by 8
Tj, C., Wf, T., Ws, W., Cc, Y., Fan, F. S., Liu, H., & Pm, C. (2000) · PubMed · Cited by 8
Tsavaris, N. B., Kosmas, C., Vadiaka, M., Kontos, A., Katsorida, M., Dimitrakopoulos, A., Zerai, A., & Koufos, C. (2001) · PubMed · Cited by 7
du Bois, A. (1998) · Medizinische Klinik - Intensivmedizin und Notfallmedizin · doi:10.1007/bf03041988 · Cited by 7
Mabro, M., & Granisétron, P. K. (1999) · PubMed · Cited by 6
Huc, P., Block, S., Carlier, D., Darloy, F., Bonneterre, M.-E., Bleuse, J., Fournier, C., & Bonneterre, J. M. (1998) · PubMed · Cited by 5
Zhang, P., Sun, Y., & Zhang, H. (1996) · PubMed · Cited by 5
Research works printed but not linked: 6
- Huc P, Block S, Carlier D et al (1998) Oral granisetron versus oral ondansetron for the prevention of nausea and vomiting induced by moderately emetogenic chemotherapies. Bull Cancer (Paris) 85:562–568
- Mabro M, Kerbrat P (1999) Etude comparative du granisetron per os et de l’ondansetron IV chez des patientes recevant une chimiotherapie pour un cancer du sein. Bull Cancer (Paris) 86:295–301
- Massidda B, Laconi S, Foddi M et al (1994) Prevention of non-cisplatin induced emesis: role of the antagonists of 5-HT3 receptors. Ann Oncol 5:204
- Mendarte L, Aguas CM, Martinez BE et al (2000) Meta-analysis of granisetron versus ondansetron: efficacy and safety in the prevention of acute emesis induced by high dose cisplatin containing schedules. Med Clin (Barcelona) 115:456–460
- Monde M, Grazie M, De Vita F et al (1994) Tropisetron vs granisetron nell’emesi acuta e ri-tardata indotta da cis-platino: dati preliminary. Tumori 80:150 (Abstr 428)
- Multinational Association for Supportive Care in Cancer (2005) Antiemetic guidelines from the Consensus Conference on Antiemetic Therapy. Perugia International Cancer Conference VII. Perugia, Italy; 29–31 March 2004. Support Care Cancer 13:77–79; 80–84; 85–96; 97–103; 104–108; 109–111; 112–116; 117–121; 122–128; 129–131
Cited by
Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update
Basch, E., Prestrud, A. A., Hesketh, P. J., Kris, M. G., Feyer, P. C., Somerfield, M. R., Chesney, M., Clark-Snow, R. A., Flaherty, A. M., Freundlich, B., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.4614 · Cited by 1,059
Antiemetic Prophylaxis for Chemotherapy-Induced Nausea and Vomiting
Navari, R. M., & Aapro, M. (2016) · New England Journal of Medicine · doi:10.1056/nejmra1515442 · Cited by 477
Jordan, K., Gralla, R., Jahn, F., & Molassiotis, A. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2013.09.073 · Cited by 192
Self-citationJordan, K., Sippel, C., & Schmoll, H.-J. (2007) · The Oncologist · doi:10.1634/theoncologist.12-9-1143 · Cited by 188
Self-citationVenkatesan, T., Levinthal, D. J., Tarbell, S. E., Jaradeh, S. S., Hasler, W. L., Issenman, R. M., Adams, K. A., Sarosiek, I., Stave, C. D., Sharaf, R. N., et al. (2019) · Neurogastroenterology & Motility · doi:10.1111/nmo.13604 · Cited by 137
Metadata
- Authors
- Jordan, K., Hinke, A., Grothey, A., Voigt, W., Arnold, D., Wolf, H.-H., & Schmoll, H.-J.
- Affiliations
- Martin Luther University Halle-Wittenberg (DE)
- WiSP Wissenschaftlicher Service Pharma GmbH (Germany) (DE)
- Mayo Clinic (US)
- Corresponding author
- Jordan, K.
- Venue
- Supportive Care in Cancer
- Published
- 2007-01-05
- Volume
- 15
- Issue
- 9
- Pages
- 1023-1033
- ISSN
- 0941-4355 (ISSN-L)
- 1433-7339
- OpenAlex
- W2013631853
- Cited by
- 93
- References
- 71
- Citations by year
- 2025: 1 · 2024: 5 · 2023: 2 · 2022: 1 · 2021: 5 · 2020: 1 · 2019: 4 · 2018: 1 · 2017: 5 · 2016: 8 · 2015: 7 · 2014: 7 · 2013: 7 · 2012: 10
- FWCI
- 1.28
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Supportive Care in Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Surgery › Nausea and vomiting management
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Keywords
- 5-HT3 receptor antagonists, chemotherapy-induced nausea and vomiting, antiemetic efficacy, granisetron, ondansetron, tropisetron, dolasetron, cisplatin-based chemotherapy, drug dose comparison, drug efficacy comparison
- MeSH terms
- Tropisetron, Antiemetics, Antineoplastic Agents, Humans, Indoles, Quinolizines, Serotonin Antagonists, Vomiting, Treatment Outcome, Ondansetron, Granisetron, Serotonin 5-HT3 Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.